PDCD1 and neoplasm: TAMs induce expansion of IL-17-producing CD4+Th17 cells to inhibit anti-tumor immunity by upregulation of PD-1, T-lymphocyte-associated protein 4 (CTLA-4), and glucocorticoid-induced TNF receptor family-related protein (GITR) (56).